Open Access

GABRQ expression is a potential prognostic marker for patients with clear cell renal cell carcinoma

  • Authors:
    • Dongjun Lee
    • Mihyang Ha
    • Chae Mi Hong
    • Jayoung Kim
    • Su Min Park
    • Dongsu Park
    • Dong Hyun Sohn
    • Ho Jin Shin
    • Hak‑Sun Yu
    • Chi Dae Kim
    • Chi‑Dug Kang
    • Myoung‑Eun Han
    • Sae‑Ock Oh
    • Yun Hak Kim
  • View Affiliations

  • Published online on: October 4, 2019     https://doi.org/10.3892/ol.2019.10960
  • Pages: 5731-5738
  • Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. Novel biomarkers of ccRCC may provide crucial information on tumor features and prognosis. The present study aimed to determine whether the expression of γ‑aminobutyric acid (GABA) A receptor subunit θ (GABRQ) could serve as a novel prognostic marker of ccRCC. GABA is the main inhibitory neurotransmitter in the brain that activates the receptor GABAA, which is comprised of three subunit isoforms: GABRA3, GABRB3 and GABRQ. A recent study reported that GABRQ is involved in the initiation and progression of hepatocellular carcinoma; however, the role of GABRQ in ccRCC remains unknown. In the present study, clinical and transcriptomic data were obtained from cohorts of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). Differential GABRQ expression levels among early (TI and II), late (TIII and IV), nonmetastatic (M0) and metastatic (M1, primary tumor) stages of ccRCC samples were then identified. Furthermore, the use of GABRQ as a prognostic gene was analyzed using Uno's C‑index based on the time‑dependent area under the curve (AUC), the AUC of the receiver operating characteristic curve at 5 years, the Kaplan‑Meier survival curve and multivariate analysis. The survival curve analysis revealed that low GABRQ mRNA expression was significantly associated with a poor prognosis of ccRCC (P<0.001 and P=0.0012 for TCGA and ICGC data, respectively). In addition, analyses of the C‑index and AUC values further supported this discriminatory power. Furthermore, the prognostic value of GABRQ mRNA expression was confirmed by multivariate Cox regression analysis. Taken together, these results suggested that GABRQ mRNA expression may be considered as a novel prognostic biomarker of ccRCC.

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lee, D., Ha, M., Hong, C.M., Kim, J., Park, S.M., Park, D. ... Kim, Y.H. (2019). GABRQ expression is a potential prognostic marker for patients with clear cell renal cell carcinoma. Oncology Letters, 18, 5731-5738. https://doi.org/10.3892/ol.2019.10960
MLA
Lee, D., Ha, M., Hong, C. M., Kim, J., Park, S. M., Park, D., Sohn, D. H., Shin, H. J., Yu, H., Kim, C. D., Kang, C., Han, M., Oh, S., Kim, Y. H."GABRQ expression is a potential prognostic marker for patients with clear cell renal cell carcinoma". Oncology Letters 18.6 (2019): 5731-5738.
Chicago
Lee, D., Ha, M., Hong, C. M., Kim, J., Park, S. M., Park, D., Sohn, D. H., Shin, H. J., Yu, H., Kim, C. D., Kang, C., Han, M., Oh, S., Kim, Y. H."GABRQ expression is a potential prognostic marker for patients with clear cell renal cell carcinoma". Oncology Letters 18, no. 6 (2019): 5731-5738. https://doi.org/10.3892/ol.2019.10960